Assessment of endothelial function by positron emission tomography

Current Cardiology Reviews

Volumn 2, Issue 2, 2006, Pages 101-107

  Alexanderson, Erick ^a,b,d   Romero, Jose Luis ^a   Ricalde, Alejandro ^a   Alexanderson, Graciela ^c   Meave, Aloha ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c SECRETARÍA DE SALUD   (Mexico)

^d NONE   (Mexico)

Author keywords

Cold pressor test; Coronary artery disease; Endothelial dysfunction; Myocardial blood flow; Positron emission tomography

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD VESSEL FUNCTION; BLOOD VESSEL WALL; COLD PRESSOR TEST; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DRUG RESPONSE; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; FUNCTIONAL ASSESSMENT; HEART HEMODYNAMICS; HEART MUSCLE BLOOD FLOW; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; NON INVASIVE PROCEDURE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 33746175359     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339406776872843     Document Type: Review

References (79)

1. Luescher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 2:3-10.
2. Gonzalez A, Rosas O, Alexanderson G et al. In: Alexanderson E Eds, Metabolic syndrome and heart disease. México, Intersistemas Co. 2004; 87-129.
3. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcoline. Nature 1980; 288: 373-6.
4. Zeiher AM, Drexler H, Wollschlaeger H, Saurbier B, Just H. Coronary vasomotion in response to sympathetic stimulation in humaas: importance of the functional integrity of the endothelium. J Am Coll Cardiol 1989; 14:1181-90.
5. Verma S, Anderson T. Fundamentals of endothelial function for clinical cardiologist. Circulation 2002; 105: 546-9.
6. Campisi R, Di Carli M. Assessment of coronary flow reserve and microcirculation: A clinical perspective. J Nucl Cardiol 2004; 11: 3-11.
7. Muzik O, Beanlands RS, Hutchins GD, Manger TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 1993; 34: 83-91.
8. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-92.
9. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23(2): 168-75.
10. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42(7): 1149-60.
11. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111(3): 363-8.
12. Schindler T, Nitzsche EU, Schelbert HR, et al. Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiac events. J Am Coll Cardiol 2005; 45(9): 1505-12.
13. Webel B, Garbers D. The guanylyl cyclase family at Y2K. Annu Rev Physiol 2000; 63: 215-33.
14. von der Leyen HE, Dzau VJ. Therapeutic potential of nitric oxide synthase gene manipulation. Circulation 2001; 103: 2760-5.
15. Münzel T, Feil R, Mülsch A, et al. Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3′,5′-cyclic monophosphate-dependent protein kinase. Circulation 2003; 108: 2172-83.
16. Epstein F. Atherosclerosis: an inflammatory disease. N Eng J Med 1999; 340(2): 115-23.
17. Paniagua O. Role of endothelial nitric oxide in shear stress-induced vasodilatation of human microvasculature. Circulation 2001; 103: 1752-9.
18. Landmesser U, Hornig B, Drexleer H. Endothelial dysfunction in hypercholesterolemia: Mechanisms, pathophysiological importance and therapeutic interventions. Semin Thromb Hemost 2000; 26: 529-638.
19. Schindler T, Nitzsche E, Olschewski M, et al. PET-Measured responses of MBF to cold pressor testing correlate with indices of coronary vasomotion on quantitative coronary angiography. J Nucl Med 2004; 45(3): 419-28.
20. Alexanderson E, Kerik E, Unzek S, Fermon S. Principles and applications of positron emission tomography in cardiology. Arch Cardiol Mex 2002; 72: 157-64.
21. Patton JA. In: Patton JA Eds, Practical FDG imaging, a teaching file. New York, Elsevier 2002; 18-36.
22. Hutchins GD. What is the best approach to quantify myocardial blood flow with PET? J Nucl Med 2001; 42(8): 1183-4.
23. 18F fluorodeoxyglucose SPECT for assessment of myocardial viability. J Nucl Cardiol 2000; 7(4): 382-7.
24. Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simple virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci 2000; 97: 2785-90.
25. 15O]water techniques. Circulation 1996; 93: 2000-6.
26. 13N-ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 1992; 86: 1004-17.
27. Di Carli M, Czernin J, Hoh CK, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation 1995; 91: 1944-51.
28. Bache RJ. Vasodilator reserve. A functional assessment of coronary health. Circulation 1998; 98: 1257-1260.
29. Prior JO, Quinones MJ, Hernandez-Pampaloni M, et al. Circulation 2005; 111(18): 2291-8.
30. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349(11): 1027-35.
31. Modena, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40(3): 505-10.
32. Kichuk MR, Seyedi N, Zhang X, et al. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulation 1996: 94: 44-51.
33. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988; 77: 43-52.
34. Kaufmann PA, Camici PG. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med 2005 46(1): 75-88.
35. Zeiher AM, Dexler H, Wollschlaeger H, Saurbier B, Just H. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 1989; 14(5): 1181-90.
36. Buus NH Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 2001; 104(19): 2305-10.
37. Nitenberg A, Ledoux S, Valensi P, Sachs R, Attali JR, Antony I. Impairment of coronary microvascular dilatation in response to cold pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes 2001; 50(5): 1180-5.
38. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003; 41: 1387-93.
39. Di Carli MF, Dorbala S, Hassan A, et al. Relation of coronary vasodilator reserve to features of the metabolic syndrome in patients with documented or at risk for coronary artery disease. Circulation 2003; 108: 399-404.
40. Rodriguez-Porcel M, Lerman LO, Herrmann J, et al. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol 2003; 23: 885-91.
41. Hamasaki S, Al Suwaidi J, Higano ST, et al. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol 2000; 35: 1654-60.
42. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323; 22-7.
43. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
44. Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990; 15: 43-51.
45. Akinoboboye OO, Chou RL, Bergmann SR, Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. J Am Coll Cardiol 2002: 40: 702-9.
46. Laine H, Raitakari OT, Niinikoski H, et al. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 1998; 32: 147-53.
47. Czernin J, Sun K, Brunken R, et al. Effect of acute and long-term smoking on myocardial blood flow reserve. Circulation 1995; 91: 2891-7.
48. Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, et al. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 2000; 102: 1233-8.
49. Campisi R, Czemin J, Schoder H, et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 1998; 98(2): 119-25.
50. Nitenberg A, Valensi P, Sachs R, et al. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographic coronary normal coronary arteries and normal left ventricular systolic function. Diabetes 1993; 42: 1017-25.
51. Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism. Am J Cardiol 1997; 80: 94-101.
52. Yokoyama I, Momomura S, Ohtake T, et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1997; 30: 1472-7.
53. Pitkanen OP, Nuutila P, Raitakari OT, et al. Coronary Flow reserve is reduced in young men with IDDM. Diabetes 1998; 47: 248-54.
54. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999; 100: 813-9.
55. Holvoet P, Mertens A, Breame P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21:844-8.
56. Kolodgie FD, Virmani R, Burke AP, et al. Pathologic assessment of the vulnerable human coronary plaque. Heart 2004; 90(12): 1385-91.
57. Sinisalo J, Paronen J, Mattila KJ, et al. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis 2000; 149: 403-11.
58. Poirier P, Eckel RH. Advanced glycation end products and coronary heart disease in type 2 diabetes. Diabetes Care 2000; 23(9): 1441-2.
59. Davidson MH, National cholesterol Education Program (NCEP) Adult Treatment Panel (ATP). A look to the future: new treatment guidelines and perspective on statins. Am J Med 2002; 112:34-41.
60. Dayanikli F, Grambow D, Muzik O, et al. Early detection of abnormal coronary flow reserve in asymptomatic mena t high risk for coronary artery disease using positron emission tomography. Circulation 1994; 90: 808-17.
61. Pitkanen OP, Raitakari OT, Niinikishi H, et al. Coronary reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol 1996; 28: 1705-11.
62. Yokoyama I, Murakami T, Ohtake T, et al. Reduced coronary flow reserve in familial hypercholesterolemia. J Nucl Med 1996; 37: 1937-42.
63. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Eng J Med 1995; 333: 1301-7.
64. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults. The Framingham Study. Am J Cardiol 1987; 59: 91-4.
65. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2508-9.
66. Grundy SM. Approach to lipoprotein management in 2001 national cholesterol guidelines. Am J Cardiol 2002; 90: 11-21.
67. Kwiterovich PO. The effect of dietary fat, antioxidants and pro-oxidants on blood lipids and lipoproteins and atherosclerosis. J Am Diet Assoc 1997; 97: 31-41.
68. Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998; 138: 229-35.
69. Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002; 90: 30-47.
70. Tincani A, Biasini C, Cattaneo R, Riboldi P. Nonorgan specific autoantibodies and heart damage. Lupus 2005; 14(9): 656-9.
71. Tenedios F, Erkan D, Lockshin M.D. Cardiac involvement in the antiphospholipid syndrome. Lupus 2005; 14(4): 691-6.
72. Delgado-Alves J, Mason J, Ames RJ, et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology 2005; 44(10): 1238-44.
73. Baller D, Notohamiprodjo G, Gleichmann U, et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999; 99: 2871-5.
74. Janatuinen T, Laaksonen R, Vexalainen R, et al. Effect of lipid lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001; 38: 561-8.
75. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 1998; 98: 1291-6.
76. Hambrecht R, Wolf A, Gielen S, et al. Effects of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 342: 454-60.
77. Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after log-term, intense risk factor modification. JAMA 1995; 274: 849-901.
78. Campisi R, Czernin J, Karpman HL, Schelbert HR. Coronary vasodilatory capacity and flow reserve in normal myocardium supplied by bypass grafts late after surgery. Am J Cardiol 1997; 80(1): 27-31.
79. Gokee N, Keaney J, Hunter L, Watkins M, Menzoian J, Vita A. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function. Circulation 2002; 105: 1567-72.